AOD-9604 vs MOTS-C
AOD-9604 is a synthetic hexadecapeptide reproducing the C-terminal lipolytic domain of human growth hormone, usually written as hGH fragment 176-191, and its pharmacology was worked out in rodent obesity models between 1993 and 2001. MOTS-c is a 16-amino-acid microprotein encoded within the mitochondrial 12S rRNA gene, identified in 2015 as a retrograde signalling molecule acting on AMPK and folate-methionine one-carbon metabolism. Both are 16 residues long and both are marketed for metabolic outcomes, which is why they are so often paired. No study has administered them together, or administered either one in a design that also tested the other. Two publications do engage both compounds: a 2026 narrative review of approved and unapproved peptides in sports medicine, and the 2026 edition of the annual anti-doping banned-substance review, which records where each sits on the World Anti-Doping Agency's 2025 Prohibited List. Neither dosed anything, so the comparison below remains indirect.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No experiment has administered AOD-9604 and MOTS-c within the same design, in any species. Two verified publications engage both compounds without dosing either. Mendias and Awan's 2026 narrative review in Sports Medicine set out the pharmacological mechanism, safety profile and regulatory status of twelve approved and unapproved peptides marketed directly to patients, listing AOD-9604 and MOTS-C alongside BPC-157, CJC-1295, follistatin-344, GHK-Cu, ipamorelin, sermorelin, SS-31, tesamorelin, thymosin beta-4 and TB-500. Its conclusion applied to the group rather than to either compound individually: favourable tissue-repair and metabolic outcomes were common in animal models, rigorous human safety data were scarce, and the potential for serious harm was real. The 2026 annual banned-substance review by Thevis, Kuuranne and Geyer placed both on the 2025 Prohibited List, AOD-9604 among growth hormone analogues and fragments prohibited at all times and MOTS-c as a newly added example within the metabolic modulators class. Both papers are surveys; neither produces comparative pharmacological data.
The 2 publications that cover both
- 01Review2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias CL, Awan TM · Sports Medicine · narrative review of twelve approved and unapproved peptides marketed direct to patients in sports medicine, AOD-9604 and MOTS-C among them
The review described the pharmacological mechanism, safety profile and regulatory status of each compound covered, naming AOD-9604 as anti-obesity drug 9604 and MOTS-C as mitochondrial ORF of the 12S rRNA type-c. The authors reported that many unapproved peptides produced favourable tissue-repair or metabolic outcomes in animal models while rigorous human safety data remained scarce, identified potential for serious harm to patients, and discussed the placebo effect and its amplification through social media as a mediator of perceived efficacy. Neither compound was administered and the two were not compared against each other.
- 02Review2026
Annual Banned-Substance Review 18th Edition-Analytical Approaches in Human Sports Drug Testing 2024/2025
Thevis M, Kuuranne T, Geyer H · Drug Testing and Analysis · annual survey of anti-doping analytical literature published between October 2024 and September 2025, framed against the World Anti-Doping Agency 2025 Prohibited List
The review recorded AOD-9604, given as hGH 176-191, among the growth hormone analogues and fragments in the peptide hormones class prohibited at all times, and noted that the peptide referred to as mitochondrial open reading frame of the 12S rRNA-c had been added as a new example to the metabolic modulators class in the 2025 edition of the Prohibited List. The paper surveyed detection methods and regulatory changes; neither compound was administered.
Side by side.
| AOD-9604 | MOTS-C | |
|---|---|---|
| Evidence maturity | Early clinical | Preclinical only |
| Studies cited here | 17 | 15 |
| Published 2023 or later | 4 | 12 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A synthetic 16-amino-acid peptide corresponding to the C-terminal domain of human growth hormone, Tyr-hGH 177-191. It is a fragment of a nuclear-encoded hormone, made synthetically for research and supply. | A 16-amino-acid microprotein encoded in the mitochondrial genome within the 12S rRNA gene. It is endogenous, its expression rises with acute exercise, and its coding region carries an East-Asian-specific polymorphism, m.1382A>C, producing a K14Q substitution. |
| Mechanism as described in the literature | Adipose-tissue lipid handling: increased lipolysis, reduced lipogenesis and increased fat oxidation in rodents. Binding experiments indicated no interaction with the growth hormone receptor, effects persisted in beta3-adrenergic receptor knock-out mice, and pooled human data showed no elevation of IGF-1. | Retrograde mitochondrial-to-nuclear signalling: targeting of the folate-methionine one-carbon cycle and activation of AMPK in the identifying paper, direct binding and activation of casein kinase 2 in skeletal muscle in later work, and mitochondrial bioenergetic effects shown in mice to depend on intact PGC-1alpha and AMPK signalling. |
| Size of the evidence base | Seventeen verified studies in this library, spanning 1993 to 2026. Primary pharmacology on the compound is concentrated between 1993 and 2015; most records since are analytical chemistry or narrative reviews rather than new experiments. | Fifteen verified studies in this library, spanning 2015 to 2026, with new primary work still appearing, including mouse mitochondrial bioenergetics and human observational cohorts published in 2026. |
| Best-characterised finding | Reduced body-weight gain and increased fat oxidation in genetically obese and diet-induced obese rodents, reported across several papers by the same group around 2000 and 2001, with the effect separated from growth hormone receptor binding and from the adverse insulin-sensitivity effects of intact growth hormone. | Prevention of diet-induced and age-dependent insulin resistance in mice in the 2015 identifying paper, and improved physical performance in young, middle-aged and old mice after administration in a 2021 report that also documented exercise-induced increases in endogenous expression in human muscle and plasma. |
| Human data | A 2013 pooled analysis of six randomised, double-blind, placebo-controlled trials reported safety and tolerability, absence of an IGF-1 effect and no negative effect on oral glucose tolerance. No standalone efficacy trial has been published, so human body-composition outcomes are absent from the indexed literature. | No controlled trial has administered the peptide to humans. Human data are observational: circulating levels measured in acute coronary syndrome, obesity, polycystic ovary syndrome, cerebral palsy and diabetic heart failure, plus a genotype association across three East Asian cohorts totalling 27,527 participants. |
| Direction of the human evidence | Consistent as far as it goes, but narrow. The published human record addresses whether the peptide is tolerated and whether it disturbs growth hormone axis and glucose measures, not whether it changes fat mass. | Inconsistent. Circulating levels have been reported lower in diabetes and polycystic ovary syndrome but higher in obesity and acute coronary syndrome, and in one cohort they did not change after surgical weight loss. Assay standardisation differs between studies, so the biomarker's interpretation is unsettled. |
| Safety signals reported | The pooled human analysis described tolerability as indistinguishable from placebo, with no anti-AOD9604 antibodies detected in patients selected for antibody assay. A separate non-clinical package reported no genotoxicity across Ames, chromosomal aberration and micronucleus assays, and no general safety concern on chronic oral administration in rats and cynomolgus monkeys. | No human administration has occurred, so no human safety profile exists. The rodent literature reports no characteristic adverse signal, but immunogenicity, pharmacokinetics and long-term effects in people are unestablished, and the 2026 sports medicine review grouped it with unapproved peptides for which rigorous human safety data are scarce. |
| Regulatory and anti-doping status | No approved medicine in any jurisdiction. Listed by the World Anti-Doping Agency among growth hormone analogues and fragments prohibited at all times, with a validated urinary detection method, identified metabolites, confirmation that it does not interfere with the growth hormone isoform immunoassay, and a case report identifying it in seized unlabelled preparations. | No approved medicine in any jurisdiction. Added as a new example to the metabolic modulators class of the 2025 Prohibited List, with a mass-spectrometric plasma detection method for doping control published in 2019. |
And what it does not.
The only publications that engage both compounds are a narrative review and an anti-doping survey, and neither administered anything, so no comparative pharmacological result exists. Read separately, the two files are close to mirror images. AOD-9604 has the older, more clinically advanced but essentially closed record: rodent lipolysis pharmacology, a pooled safety and tolerability analysis from six placebo-controlled human trials, a non-clinical toxicology package, and then two decades in which almost all new publication has come from doping-control laboratories rather than from anyone testing whether it works. MOTS-c has the newer and still-expanding record, with a defined endogenous role, mechanistic depth across AMPK, casein kinase 2 and PGC-1alpha, and genuine human involvement, but that human involvement is observational measurement of a molecule the body makes, not a trial of a molecule given to anyone. One has human safety data and no published efficacy; the other has human association data and no administration at all. Both are prohibited in sport.
Common questions.
- Has any study given both AOD-9604 and MOTS-c to the same animals or the same participants?
No. Searches of PubMed and Europe PMC full text located only two publications that name both, and neither administered either compound. One is a 2026 narrative review of approved and unapproved peptides in sports medicine that covers twelve compounds including these two; the other is the 2026 annual banned-substance review, which records where each sits on the 2025 Prohibited List. There is no combination study, no comparative efficacy experiment and no published account of an interaction between them.
- Both are sixteen amino acids long. Are they related?
Only in length. AOD-9604 reproduces the C-terminal region of human growth hormone, a nuclear-encoded hormone, and was synthesised as a fragment of that sequence. MOTS-c is encoded inside the mitochondrial 12S rRNA gene and is translated from mitochondrial DNA. They share no sequence homology, no proposed receptor or target in common, and their literatures cite entirely different mechanistic pathways. The coincidence of length carries no reported biological significance.
- Which one has the stronger human evidence?
Neither has evidence that a compound was given to people and produced a measured benefit. AOD-9604 has the stronger human safety record, since a pooled analysis covered six randomised, double-blind, placebo-controlled trials, but no efficacy report from that programme was ever published in an indexed journal. MOTS-c has more human participants in its literature overall, including a genotype meta-analysis across 27,527 people, but every one of those studies measured endogenous levels or genotype rather than administering the peptide.
- What did the sports medicine review actually conclude about these compounds?
It reached a conclusion about the class rather than about either compound. Reviewing twelve approved and unapproved peptides, the authors reported that many unapproved ones show favourable tissue-repair or metabolic outcomes in animal models while rigorous human safety data remain scarce, and noted potential for serious harm to patients. They also discussed the placebo effect as a mediator of perceived efficacy and the role of social media in amplifying it, and offered a framework for clinicians discussing these compounds with patients.
- Why is MOTS-c a recent addition to the Prohibited List while AOD-9604 has been listed for years?
The annual banned-substance review records MOTS-c as one of several new examples added to the 2025 edition, within the metabolic modulators class, whereas AOD-9604 has long appeared under growth hormone analogues and fragments in the peptide hormones class. The timing reflects when each compound drew analytical and regulatory attention: AOD-9604 detection work and immunoassay interference testing date from 2013 onward, while the plasma detection method for MOTS-c was published in 2019.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.